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AXL-associated tumor inﬂammation as a poor prognostic
signature in chemotherapy-treated triple-negative breast cancer
patients
Giulia Bottai1, Carlotta Raschioni1, Borbála Székely2, Luca Di Tommaso3, Attila M Szász2, Agnese Losurdo4, Balázs Győrffy5,6, Balázs Ács2,
Rosalba Torrisi4, Niki Karachaliou7, Tímea Tőkés2, Michele Caruso8, Janina Kulka2, Massimo Roncalli3,9, Armando Santoro4,9,
Alberto Mantovani9,10, Rafael Rosell7,11,13, Jorge S Reis-Filho12,13 and Libero Santarpia1
A subgroup of triple-negative breast cancer (TNBC) shows epithelial-to-mesenchymal transition (EMT) features, which are sustained
by the interaction between cancer cells and tumor-associated macrophages (TAMs). In this study, the clinical relevance of 30 EMT-
related kinases and the potential cross-talk with TAMs were investigated in a cohort of 203 TNBC patients treated with adjuvant
chemotherapy. The prognostic value of the evaluated markers was validated in two independent cohorts of TNBC patients treated
with adjuvant chemotherapy (N= 95; N= 137). In vitro, we investigated the potential synergism between cancer cells and TAMs. We
found that the EMT-related kinase AXL showed the highest correlation with the frequency of CD163-positive macrophages
(rS = 0.503; Po0.0001). Relapsing TNBC patients presented high expression of AXL (Po0.0001) and CD163 (Po0.018), but only AXL
retained independent prognostic signiﬁcance in multivariate analysis (relapse-free survival, P= 0.002; overall survival P= 0.001).
In vitro analysis demonstrated that AXL-expressing TNBC cells were able to polarize human macrophages towards an M2-like
phenotype, and modulate a speciﬁc pattern of pro-tumor cytokines and chemokines. Selective AXL inhibition impaired the activity
of M2-like macrophages, reducing cancer cell invasiveness, and restoring the sensitivity of breast cancer cells to chemotherapeutic
drugs. These data suggest that the EMT-related kinase AXL overexpressed in cancer cells has prognostic signiﬁcance, and
contributes to the functional skewing of macrophage functions in TNBC. AXL inhibition may represent a novel strategy to target
cancer cells, as well as tumor-promoting TAMs in TNBC.
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INTRODUCTION
Triple-negative breast cancer (TNBC) is clinically deﬁned by the
lack of expression of estrogen and progesterone receptors, and no
overexpression/ampliﬁcation of HER2. This subgroup of tumors is
usually characterized by an aggressive phenotype associated with
an increased risk of early recurrence with distant metastasis
to visceral organs and poor prognosis.1,2 Burgeoning evidence
demonstrates that TNBC is a very heterogeneous disease,
encompassing different molecular entities.3,4 Current treatment
approaches are limited to cytotoxic chemotherapy due to the lack
of speciﬁc therapeutic targets.4,5 Even though TNBC patients are
initially responsive to chemotherapy, the long-term results are not
satisfactory.1,2,4 Therefore, the identiﬁcation of reliable prognostic
markers in chemotherapy-treated patients, as well as novel
targetable signaling pathways, may allow a better stratiﬁcation
of TNBC patients into different risk groups and the development
of novel treatment strategies.
A subgroup of TNBC shows epithelial-to-mesenchymal transi-
tion (EMT) features, leading to tumor progression and resistance
to chemotherapy.1–5 Early tumor recurrences, driven by
chemotherapy-resistant cancer cells, represent a prominent cause
of poor outcome in TNBC. In this context, EMT allows tumor cells
to avoid apoptosis and cellular senescence, increasing tumor cell
invasive properties and drug resistance.1,6–8
Growing evidence indicates that EMT is induced by different
biological mechanisms, and that the mutual interaction between
cancer cells and the surrounding microenvironment is a crucial
step supporting the entire EMT process.9,10 Tumor cells that
undergo EMT regulate the phenotype and the activity of non-
malignant stromal cells, particularly tumor-associated macro-
phages (TAMs), contributing to cancer progression and metastatic
spread.11,12 TAMs are able to affect the behavior of malignant
cells, and to modulate the functions of tumor-inﬁltrating
lymphocytes, overall promoting tumor progression and inﬂuen-
cing therapy response.12–19 In particular, stromal TAMs with
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pro-tumor functions, resembling the phenotype of M2-polarized
macrophages, have been shown to be capable of inducing EMT,
ultimately establishing a positive local feedback loop that sustains
cancer cells invasiveness, indirectly inﬂuencing the response to
chemotherapy.10–19 Conversely, conventional chemotherapy has
been demonstrated to contribute to the modulation of the tumor
microenvironment by inducing the recruitment of TAMs at the
tumor site and by reducing therapy efﬁcacy in breast cancer
patients.15–20
Even though the interaction between cancer cells with mesench-
ymal traits and TAMs is emerging as a crucial factor in tumor
progression and response to therapy, the clinical relevance of this
cross-talk in TNBC is still poorly understood. In this study, we ﬁrst
evaluated the expression of several kinases involved in EMT in a
large cohort of TNBC patients treated with anthracycline–taxane-
based adjuvant chemotherapy. Subsequently, we assessed the
clinical relevance of the most signiﬁcant EMT-related kinase, the
receptor AXL, validating its prognostic and functional role in addi-
tional independent cohorts of TNBC and by in vitro assays. Finally,
we evaluated the correlation between AXL and TAMs, investigating
speciﬁc mechanisms by which TNBC cells and macrophages coope-
rate to inﬂuence tumor progression and response to therapy.
RESULTS
The receptor tyrosine kinase AXL is positively associated with
macrophage inﬁltration in TNBC
To evaluate the potential relationship between cancer cells with
mesenchymal features and the presence of TAMs in breast tumor
stroma, we selected 30 relevant EMT-related kinases and
correlated their expression with the expression of the pan-
macrophage marker CD68 in a cohort of 203 TNBC patients
(Supplementary Tables 1 and 2). We found that AXL was the most
signiﬁcant kinase correlated with the frequency of CD68-positive
TAMs in the internal cohort of 203 TNBC patients (Spearman’s
coefﬁcient, rS = 0.405; Bonferroni-adjusted P= 0.007; Supplemen-
tary Figure 1a; Supplementary Table 2). We conﬁrmed this positive
correlation also at the protein level in the same cohort (rs = 0.342;
Po0.0001; Supplementary Figure 1b), and by analyzing
gene expression data from three publicly available TNBC data
sets (N= 311; rS = 0.360; Po0.0001; Supplementary Figure 1c;
Supplementary Table 1).
Furthermore, considering the potential association between AXL
expression and tumor immune response, we evaluated the clinical
signiﬁcance of global macrophage content in the internal cohort
of TNBC patients. We found a higher content of CD68-positive
macrophages in TNBC patients who experienced recurrence
within 36 months after surgery compared with non-recurrent
patients (55.3% vs. 38.5%, P= 0.045; Figure 1a; Table 1). No
statistically signiﬁcant association between the presence of CD68-
positive macrophages and other clinicopathological parameters
was, however, identiﬁed (Table 1). Furthermore, Kaplan–Meier
analysis showed no prognostic relevance of CD68-positive
macrophage count in terms of relapse-free survival (RFS) and
overall survival (OS) in TNBC patients (Figure 1b).
AXL correlates with M2-polarized macrophages and is an
independent prognostic marker in TNBC
To evaluate the potential role of AXL in the regulation of cancer-
related inﬂammation in TNBC, we analyzed co-regulated genes
Figure 1. High inﬁltration of CD68-positive cells is associated with tumor relapse but not with survival in triple-negative breast cancer.
(a) Representative immunohistochemical staining of CD68 in tumor samples from TNBC patients with recurrence (left panel) and without
recurrence (right panel). Scale bars represent 50 μm. (b) Kaplan–Meier analysis for relapse-free survival (left panel) and overall survival (right
panel) according to the content of CD68-positive cells in tumor stroma. TNBC patients (N= 203) were stratiﬁed by absent/moderate (0–2) or
dense (3) macrophage inﬁltration. Curves were compared using log-rank test. P values and HR (95% CI in parentheses) are shown.
CI, conﬁdence interval; HR, hazard ratio; TNBC, triple-negative breast cancer.
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and pathways using the SEEK platform and the Ingenuity Pathway
Analysis software. This analysis demonstrated that, besides its
well-known role in EMT, AXL is strongly co-expressed with genes
involved in several immune functions (Supplementary Figure 2a;
Supplementary Table 3), conﬁrming AXL as a key factor of a gene
network that inﬂuence both EMT and tumor-associated inﬂamma-
tion in TNBC.
Given the plasticity and heterogeneity of macrophages, we next
investigated the role of AXL in shaping the inﬂammatory tumor
microenvironment in TNBC. Two distinct immune gene modules
reﬂecting the polarization of anti-tumor M1 or pro-tumor M2 macro-
phages were assembled based on a literature review and analyzed
using SEEK (Supplementary Figure 2b,c and Supplementary Table
4). We found that AXL was consistently co-expressed with genes
enclosed in the M2-related module (co-expression score = 1.013;
P= 0.013), whereas it showed no relationship with M1-polarized
macrophages in TNBC (Supplementary Figure 2b,c and
Supplementary Table 5), suggesting that AXL expressed by tumor
cells may be involved in the switch towards an M2 phenotype,
thus sustaining the pro-tumor activity of TAMs.
To conﬁrm these observations, we analyzed the expression of
AXL and the M2 macrophage marker CD163 in the internal cohort
of 203 TNBC patients, which revealed a positive correlation
between AXL and the inﬁltration of CD163-positive cells
(rS = 0.503; Po0.0001; Figure 2a). Furthermore, TNBC patients
who experienced distant relapse had a signiﬁcant higher
expression of both AXL and CD163 compared with patients
without recurrence (Po0.0001; P= 0.018, respectively; Figure 2b
and c; Table 1). High levels of AXL expression were also associated
with lymph node positivity (P= 0.042), and interestingly with
metastasis to visceral organs as the ﬁrst sites of distant recurrence
(P= 0.036; Table 1).
To assess the prognostic value of AXL and CD163 in TNBC
patients, we performed Kaplan–Meier and Cox univariate regres-
sion analyses in the internal cohort of TNBC patients (N= 203;
Figure 2d,e and Supplementary Table 6). We found that patients
with high levels of AXL protein expression had signiﬁcant shorter
RFS and OS (log-rank P= 0.0002; hazard ratio (HR) = 3.44; 95%
conﬁdence interval (CI), 1.78–6.65 for RFS; log-rank P= 0.0003;
HR= 3.38; 95% CI, 1.75–6.50 for OS; Figure 2c and Supplementary
Table 6), whereas CD163 was associated with RFS only (log-rank
P= 0.029; HR = 2.03; 95% CI, 1.08–3.83; Figure 2d and Supple-
mentary Table 6). Cox multivariate regression analysis, adjusted for
age at diagnosis, histological grade, lymph node status, tumor
size, and tumor stage, demonstrated that only AXL expression
remained an independent poor prognostic factor for RFS and OS
in TNBC patients treated with adjuvant chemotherapy, along with
lymph node status, whereas CD163 only retained a positive trend
for reduced RFS (Table 2). Multivariate Cox analysis performed in
an additional independent cohort of 95 chemotherapy-treated
TNBC patients, and also analyzing AXL as a continuous variable,
conﬁrmed the prognostic signiﬁcance of AXL for both RFS and OS
(Supplementary Table 7 and Supplementary Table 8).
We next assessed the prognostic value of AXL by analyzing the
gene expression data from 137 TNBC patients treated with
adjuvant chemotherapy (Supplementary Table 1). We conﬁrmed
that AXL expression was consistently associated with reduced RFS
(log-rank P= 0.008; HR = 2.3; 95% CI, 1.20–4.30; Supplementary
Figure 3a). We also found that AXL expression did not correlate
with expression levels of the proliferation marker MKI67 (Pearson’s
coefﬁcient, r= 0.014; Supplementary Figure 3b).
AXL-overexpressing breast cancer cells and M2-like macrophages
reciprocally interact in vitro
To characterize the expression of AXL in vitro, we analyzed the
expression of the tyrosine kinase, EMT (CDH1 and VIM), and basal
(EGFR, KRT5, and KRT6A) markers in 15 breast cancer cell lines by
quantitative real-time PCR (qRT-PCR; Figure 3a). We demonstrated
that AXL expression was higher in all triple-negative mesenchy-
mal-like breast cancer cell lines, compared with luminal/epithelial
cells (Figure 3a). High levels of AXL expression were also found in
two triple-negative basal-like cells (Figure 3a).
Then, we investigated the biological mechanisms underlying
the cross-talk between AXL-expressing breast cancer cells and
TAMs, and its impact on tumor progression and anticancer drug
resistance. To identify the soluble factors potentially mediating the
interaction between macrophages and breast cancer cells, we
measured the release of several major cytokines/chemokines by
macrophages exposed to the conditioned medium (CM) derived
from the AXL-expressing breast cancer cell lines HCC38, MDA-
MB-231, and MDA-MB-436, and from the AXL-negative MCF-7 cells.
We found that the medium of macrophages treated with the CM
derived from AXL-expressing cells, especially from mesenchymal-
like cells, was enriched for tumor-promoting mediators, including
CCL18, and IL-10, compared with that from macrophages treated
with MCF-7-CM (Figure 3b). Conversely, the presence of AXL-
expressing cells did not affect the release of IL-12, which is
commonly associated with the M1 phenotype (Figure 3b).
Mesenchymal-like cells also induced an increased production of
the AXL ligand Gas6 (Po0.05; Figure 3b), and a positive trend was
also observed for basal-like cells, although not reaching statistical
signiﬁcance (Figure 3b). Consistently, we found that Gas6 was
signiﬁcantly released from in vitro polarized M2-like macrophages,
but not from M1-like cells (P= 0.014; Figure 3c). These results may
suggest that the interaction between M2 TAMs and mesenchymal
TNBC cells could be partially modulated by the AXL/Gas6
signaling. To further investigate the ability of AXL-expressing
TNBC cells to promote macrophage polarization towards a pro-
tumor phenotype, we analyzed the expression of the M2 speciﬁc
markers CD206 and CD163 by ﬂow cytometry (Figure 3d). AXL-
expressing mesenchymal-like TNBC cells, but not MCF-7, were able
to polarize macrophages towards an M2 phenotype (Figure 3d,
upper panel). We also found that AXL-expressing basal-like cells
can induce these phenotypic changes in macrophages, although
to a lesser extent than mesenchymal-like cells, whereas the
polarizing effect of AXL-negative basal-like cells was marginal
(Supplementary Figure 4), suggesting that AXL may sustain the
cancer inﬂammation cross-talk beyond its primary role in EMT.
Noteworthy, the capability of MDA-MB-231 cells to change the
expression of these surface markers was impaired by the selective
inhibition of AXL with R428 (Figure 3d, lower panel). Consistently,
we found that R428-treated MDA-MB-231 cells showed reduced
expression of vimentin (P= 0.008), CCL2 (P= 0.008), IL6 (P= 0.024),
oncostatin M (OSM, P= 0.019), and TGFB2 (P= 0.029) as compared
with untreated cells (Figure 3e), indicating that AXL may
contribute to the recruitment, and the polarization of macro-
phages into M2 cells by increasing the release of speciﬁc cytokines
and chemokines.
Afterwards, we evaluated the relevance of the reciprocal cross-
talk between M2 TAMs and cancer cells for tumor progression and
chemotherapy response. We demonstrated that the CM from
M2-polarized macrophages enhanced MDA-MB-231 cell migration
(P= 0.020; Figure 4a,b), and increased the resistance of MDA-
MB-231 and HCC38 TNBC cells to paclitaxel (P= 0.028; P= 0.039,
respectively) and doxorubicin (P= 0.043; P= 0.029, respectively;
Figure 4c). Importantly, AXL inhibition with R428 reduced the
migratory capacity (P= 0.036, Figure 4a,b) and restored the
sensitivity of MDA-MB-231 and HCC38 cells to paclitaxel
(P= 0.012; P= 0.019, respectively) and doxorubicin (P= 0.027;
P= 0.020, respectively; Figure 4c). In addition to AXL inhibition,
the treatment with R428 affected the activation of other
oncogenic pathways, including AKT, ERK1/2, and SRC signaling,
suggesting possible cross-talks and escape mechanisms to AXL
inhibition in TNBC (Figure 4d). Collectively, these data suggest that
the interaction between M2 TAMs and TNBC cells through AXL has
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Figure 2. AXL expression correlates with the inﬁltration of CD163-positive cells in tumor stroma and is associated with survival in triple-
negative breast cancer. (a) A scatter diagram shows a positive correlation between immunohistochemical staining of AXL and CD163 in TNBC
(N= 203; Spearman’s coefﬁcient, rS= 0.503; Po0.0001). (b) Representative immunohistochemical staining of AXL and CD163 in tumor samples
of serial sections from TNBC patients with recurrence (left panel) and without recurrence (right panel). Scale bars represent 50 μm. (c)
Representative pictures of double immunoﬂuorescent staining and confocal microscopy of TNBC sections, showing that AXL-expressing
cancer cells (green) are in close contact with adjacent stromal TAMs (red). Scale bars represent 50 μm. (d) Kaplan–Meier analysis for relapse-
free survival (left panel) and overall survival (right panel) according to AXL immunohistochemical score. TNBC patients (N= 203) were stratiﬁed
by low (0–4) or high (6–9) AXL expression. (e) Kaplan–Meier analysis for relapse-free survival (left panel) and overall survival (right panel)
according to the content of CD163-positive cells in tumor stroma. TNBC patients (N= 203) were stratiﬁed by absent/moderate (0–2) or dense
(3) CD163-positive macrophage inﬁltration. Curves were compared using log-rank test. P values and HR (95% CI in parentheses) are shown.
CI, conﬁdence interval; HR, hazard ratio; TNBC, triple-negative breast cancer.
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Table 2. Multivariate Cox regression analysis of AXL and CD163 for relapse-free survival and overall survival in triple-negative breast cancer (N= 203)
Variable HR 95% CI P valuea HR 95% CI P valuea
Relapse-free survival Overall survival
AXL 2.84 1.45–5.55 2.20E−03 3.09 1.58–6.06 1.00E−03
Age 0.88 0.46–1.69 7.11E− 01 1.08 0.57–2.07 8.09E− 01
Grade 1.68 0.69–4.11 2.53E− 01 2.06 0.84–5.09 1.16E− 01
Nodal status 2.53 1.01–6.31 4.72E− 02 2.62 1.05–6.55 3.98E−02
Tumor size 1.33 0.69–2.58 3.97E− 01 1.17 0.61–2.25 6.30E− 01
Tumor stage 1.72 0.81–3.66 1.60E− 01 1.67 0.78–3.57 1.88E− 01
CD163 1.85 0.96–3.55 6.58E− 02 1.63 0.85–3.12 1.40E− 01
Age 0.95 0.50–1.80 8.72E− 01 1.16 0.61–2.20 6.45E− 01
Grade 1.68 0.68–4.13 2.60E− 01 1.90 0.77–4.73 1.65E− 01
Nodal status 2.90 1.18–7.13 2.02E−02 3.08 1.25–7.59 1.43E−02
Tumor size 1.36 0.70–2.65 3.60E− 01 1.19 0.62–2.30 5.99E− 01
Tumor stage 1.54 0.74–3.22 2.48E− 01 1.41 0.67–2.94 3.66E− 01
Abbreviations: CI, conﬁdence interval; HR, hazard ratio.
aSigniﬁcant P values are given in bold.
Multivariate analysis adjusted for age (⩾50 vs. o50), histological grade (G3 vs. G1–2), nodal status (1 vs. 0), tumor size (420 mm vs. ⩽ 20 mm), and tumor stage
(III vs. I–II).
Figure 3. AXL-overexpressing breast cancer cells promote the polarization of M2 macrophages. (a) Expression analysis of AXL, EMT (CDH1 and
VIM), and basal (EGFR, KRT5, and KRT6A) markers in 15 breast cancer cell lines by qRT-PCR. Gene expression levels were visualized in a heatmap.
(b) Cytokine levels in the media of macrophages cultured in the absence or presence of MCF-7- or TNBC cell-derived conditioned medium
(CM) measured by ELISA. P values were obtained using a two-tailed Student’s t-test (mean± s.d., N= 4 experiments; *Po0.05; **P⩽ 0.01).
(c) ELISA analysis of Gas6 in the medium of in vitro polarized human macrophages (Mφ). P values were obtained using a two-tailed Student’s
t-test (mean± s.d., N= 4 experiments; **P⩽ 0.01). (d) Flow cytometric analysis of the M2 markers CD163 and CD206 in human monocytes
cultured in the absence (pink) or presence of MCF-7-CM (blue), MDA-MB-231-CM (green; upper panel), or R428-treated MDA-MB-231-CM
(orange; lower panel) for 6 days. Gray histograms represent staining with isotype controls. The histograms are representatives of ﬁve
independent experiments. (e) Heatmap showing the effect of R428 on the expression of EMT markers and relevant cytokines/chemokines in
MDA-MB-231 cells (three biological replicates were shown). Signiﬁcant genes were indicated with an asterisks (*Po0.05; **P⩽ 0.01). ELISA,
enzyme-linked immunosorbent assay; EMT, epithelial-to-mesenchymal transition; TNBC, triple-negative breast cancer.
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an important role in supporting tumor progression and
chemoresistance.
DISCUSSION
The tumor microenvironment is of paramount importance in
breast cancer progression, and accumulating evidence indicates
an emerging role of the cross-talk signaling between mesench-
ymal cancer cells and TAMs. In fact, EMT and TAMs provide
invasive and metastatic capabilities to tumor cells and modulate
the tumor microenvironment, leading to the suppression of anti-
cancer immune response, and limiting the effects of cytotoxic
chemotherapy.6–11 TNBC, which is often characterized by the
presence of both EMT and TAMs, is a good model to explore
potential molecular markers maintaining the biological inter-
sections between these two signalings.9–12 In this study, we
demonstrated that the receptor AXL was the most signiﬁcant EMT-
related kinase associated with macrophage cells in the tumor
stroma of TNBC. This receptor is emerging as an important effector
of the EMT program, and its activation is responsible for triggering
important oncogenic pathways, such as PI3K/AKT/mTOR, NF-κB,
EGFR, and MAPK cascades, involved in cell proliferation, survival,
and invasion.21–26 In line with different studies on human cancer,
we found that the increased expression of AXL signiﬁcantly
correlated with poor outcome in TNBC.21–28 High levels of AXL
were associated with reduced RFS and OS in TNBC patients
treated with anthracycline–taxane-based adjuvant chemotherapy.
Interestingly, AXL overexpression was associated with distant
tumor recurrence, particularly to visceral organs, indicating a
speciﬁc route of tumor dissemination for a subset of these tumors.
AXL has been previously shown to be one of the most
differentially expressed genes in the mesenchymal stem-like
subtype compared with other subgroups of TNBC.29 Our data
demonstrated that the expression of AXL was a speciﬁc feature of
TNBC cells, especially those with mesenchymal features, sustain-
ing the key role of AXL in the activation of the EMT program, and
in mediating cancer cell aggressiveness.21–24,30 Furthermore, we
showed that AXL was involved in the modulation of several
immune pathways, including leukocyte migration and chemotaxis,
macrophage activation, and agranulocyte adhesion and
Figure 4. M2-polarized macrophages sustain tumor aggressiveness and inﬂuence drug sensitivity of AXL-overexpressing breast cancer cells.
(a) Wound-healing assays were conducted with untreated or R428-treated MDA-MB-231 cells cultivated in the absence (control medium) or
presence of conditioned medium (CM) derived from in vitro polarized M2 macrophages. (b) Statistical analysis of wound closure. Gap size at
0 h was set to 100% and percentage of closed wound was calculated after 24 h. (c) M2-polarized macrophages increase the resistance of
HCC38 and MDA-MB-231 cells to paclitaxel (Pac) and doxorubicin (Dox) treatments compared with cells treated with control medium, whereas
the selective inhibition of AXL with R428 restores drug sensitivity in TNBC cells. (d) Western blot with the indicated antibodies of lysates from
MDA-MB-231 cells treated with 1 μmol/l R428 at different time points. β-Actin was used as a loading control. All P values were obtained using a
two-tailed Student’s t-test (mean± s.d., N= 3 experiments; *Po0.05; **P⩽ 0.01).
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diapedesis, further supporting the biological relevance of the
interaction between AXL-expressing cancer cells and cancer-
related immune responses in TNBC.9–15
Previous studies reported that CD68-positive TAMs are a
potential prognostic marker in breast cancer.17,22,31,32 However,
we found that CD68-positive macrophages in tumor stroma
mildly correlated with tumor relapse and were not signiﬁcantly
associated with TNBC patients outcome. Therefore, given potential
differences in the evaluation of protein expression among studies,
the clinical signiﬁcance and utility of CD68 expression in TNBC
remains uncertain. These data also highlight the concept that
CD68 probably does not accurately reﬂect the presence and
function of distinct macrophage subpopulations within the tumor
stroma, at least in breast cancer.18,33,34 Consequently, our results
advocate the importance to further evaluate the biological role
and functions of different macrophage subpopulations in breast
cancer. Indeed, macrophages exhibit remarkable functional and
phenotypic plasticity, with activated M2-like cells displaying
tumor-promoting activities.14,22 Accordingly, most human tumors
exhibit TAMs with an M2-like phenotype, promoting EMT, and
contributing to tumor progression and drug resistance.11–20,35 In
agreement with these reports, we found that the massive
presence of M2 macrophages correlated with an aggressive beha-
vior of TNBC. Moreover, AXL was signiﬁcantly co-expressed with
genes associated with M2 macrophages, and positively correlated
with the inﬁltration of CD163-positive M2 cells, suggesting an
important relationship between AXL-expressing cells and TAMs
with pro-tumor activity in a subgroup of TNBC.
The cross-talk between mesenchymal cancer cells and tumor
microenvironment is recognized as a key factor in tumor
progression in several tumors.10–12,14,30 However, we demon-
strated that CD163-positive M2 TAMs did not retain their
prognostic signiﬁcance in multivariate analysis. Our data suggest
that the CD163-positive embedded stromal cells likely have a role
in sustaining the aggressiveness of cancer cells, but the presence
of pro-tumor macrophages alone may not be sufﬁcient to affect
the outcome of TNBC patients. Although the mechanisms
underlying the link between cancer cells and TAMs are complex
and difﬁcult to dissect in vitro, we observed the reciprocal nature
of this interaction sustained by AXL. Our data show that
AXL-positive TNBC cells with mesenchymal traits activate human
macrophages to an M2-like phenotype, modulating a speciﬁc
pattern of pro-tumor cytokines and chemokines. Indeed,
mesenchymal-like cells were able to increase the release of
CCL18 and IL-10, which are known macrophage-derived mediators
of metastatic dissemination and resistance to chemotherapy
in breast cancer.36,37 Furthermore, we demonstrated that the
selective inhibition of AXL with R428 impaired the ability of
mesenchymal cells to induce the polarization of macrophages, by
reducing the release of CCL2, IL-6, oncostatin M, and TGF-β, which
are well-known inducers of the M2 phenotype.13,38 In addition,
AXL may be also involved in the recruitment of macrophages at
the tumor site, increasing the production of CCL2 that functions as
a monocyte chemoattractant protein.39 Noteworthy, we found
that AXL-expressing mesenchymal-like cells were also capable of
inducing the release of the AXL ligand Gas6, which is selectively
secreted by M2-type macrophages. Our results suggest that the
AXL/Gas6 signaling may have a role in modulating the interaction
between mesenchymal TNBC cells and M2 TAMs, and support
previous ﬁndings, indicating that tumor cells induced inﬁltrating
TAMs to increase the production of Gas6, promoting cell growth
and metastasis in different cancer models.40 Even though AXL can
be activated by Gas6, alternative ligand-independent mechan-
isms, including the interaction with EGFR, which is frequently
express in TNBC, have been demonstrated.1,24–26 Therefore,
although the biological modalities of AXL action should be further
investigated, our results suggest that TNBC cells with mesench-
ymal features may ‘educate’ inﬁltrating TAMs to support tumor
progression, and that targeting AXL may be a novel strategy to
reduce both EMT and the pro-tumor activity of TAMs in TNBC.
Finally, we demonstrated that the presence of M2-polarized
macrophages enhanced the migratory potential and chemoresis-
tance of TNBC cells, whereas the selective pharmacological
inhibition of AXL was able to drastically reduce cell aggressive-
ness, and to restore response to chemotherapeutic drugs,
including taxanes and anthracyclines. These results are in
agreement with recent ﬁndings showing that inﬁltrating macro-
phages reduced the primary breast tumor drug response, and that
R428 enhanced the efﬁcacy of anti-mitotic drugs in mesenchymal-
like lung and breast cancer cells.37,41 Noteworthy, AXL inhibition
also affected the activation of other oncogenic pathways,
providing the evidence of cross-talk signaling between different
pathways and the activation of compensatory feedback networks.
We showed that AXL was also expressed in basal-like breast cancer
cells. Even though the effect of AXL-expressing basal-like cells on
macrophage polarization was mild compared with that of
mesenchymal-like cells, TAMs were equally able to induce chemo-
resistance in both TNBC models. These ﬁndings suggest that,
beyond the role of mesenchymal-like cells in supporting the cross-
talk with TAMs, AXL inhibition could be a potential therapeutic
strategy for a broader range of patients with AXL-expressing TNBC.
Our study has some limitations. Even though we provide
evidence of the involvement of AXL kinase in macrophage
polarization, the speciﬁc requirement of AXL for the interaction
with TAMs, the identiﬁcation of the soluble mediators of this cross-
talk, and the potentially distinct biological role of different
subtypes of TNBC cells warrant further studies. Given the
retrospective nature of this study, and to determine the potential
heterogeneity of treatment effects associated with AXL functions,
our ﬁndings would need to be further validated in a prospective
clinical trial. Despite these limitations, our results suggest that AXL
is a prognostic indicator of outcome in TNBC treated with
chemotherapy. Furthermore, AXL supports the pro-tumor activity
of M2-type macrophages, inducing tumor progression and
resistance to chemotherapy. Overall, our data provide support
for the use of AXL targeted therapy to reduce tumor aggressive-
ness, overcome chemotherapy resistance, and impair the cross-
talk between cancer cells and TAMs, in patients with TNBC
overexpressing AXL.
MATERIALS AND METHODS
Patients’ cohorts and tumor samples
Formalin-ﬁxed, parafﬁn-embedded (FFPE) tissues were retrospectively
collected from 203 patients with histologically conﬁrmed invasive ductal
TNBC, who underwent surgery at Humanitas Clinical and Research Institute
(Rozzano-Milan, Italy) from 2006 to 2011. To validate our ﬁndings, an
additional independent cohort of TNBC samples (N= 95) who underwent
surgery at Humanitas Oncology Center of Catania (Catania, Italy; N= 59)
and Semmelweis University Hospital (Budapest, Hungary; N= 36) from
1999 to 2008 was used. Estrogen, progesterone, and HER2 status were
centrally assessed by immunohistochemistry and/or ﬂuorescence in situ
hybridization in ~ 90% of patients at Humanitas Clinical and Research
Institute. The study was approved by the ethical committees of the Italian
and Hungarian Institutions. The REporting of tumor MARKer Studies
(REMARK) guidelines were followed in reporting results of this study.42 All
patients were treated with adjuvant anthracycline–taxane-based che-
motherapy. Clinical characteristics of patients included in this study are
presented in Supplementary Table 1.
Immunohistochemistry, immunoﬂuorescence, and evaluation of
staining
FFPE sections (3 μm) from TNBC patients included in the discovery
(N= 203) and validation (N= 95) cohorts were incubated with AXL (R&D
Systems, Minneapolis, MN, USA), CD163 (Novocastra, Newcastle, UK), and
CD68 (Dako, Glostrup, Denmark) antibodies for 1 h at room temperature.
CD68 and CD163 staining in the tumor stroma was scored using a
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four-tiered system ranging from 0 (absent) to 3 (dense).43 AXL staining was
scored semiquantitatively, as previously described.21 In brief, intensity was
recorded as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3
(strong staining), and the proportion of positive tumor cells was deﬁned as
the following: 0o1%; 1 = 1–9%; 2 = 10–49%; and 3⩾ 50%. A composite
staining index was calculated by multiplying the intensity by the
percentage of positive cells, and patients were stratiﬁed by low (0–4) or
high (6–9) AXL expression for statistical analyses. The optimal cut-off point
was determined by maximizing the sum of sensitivity and speciﬁcity. AXL
expression was also evaluated as a continuous variable. For immuno-
ﬂuorescence, sections were incubated with AXL and CD163 primary
antibodies, and then with donkey anti-goat Alexa 488-conjugated (Life
Technologies, Carlsbad, CA, USA) and donkey anti-mouse Alexa-647-
conjugated (Life Technologies) antibodies. Slides were counterstained with
4,6-diamidino-2-phenylindole (DAPI). Images were captured using an
Olympus BX53 or Olympus Fluoview FV1000 laser scanning confocal
microscope (Olympus, Tokyo, Japan). Detailed procedures for immuno-
histochemistry and immunoﬂuorescence are described in Supplementary
Methods.
Expression analysis by quantitative reverse-transcription PCR
On the basis of a comprehensive literature review, we selected the 30 most
functionally relevant kinases associated with EMT in breast cancer
(Supplementary Table 2), and evaluated their expression by qRT-PCR, as
described in Supplementary Methods. We also assessed the expression of
conventional EMT (CDH1 and VIM), and basal (EGFR, KRT5, and KRT6A)
markers, and of a panel of cytokines/chemokines in breast cancer cell lines.
The expression of selected genes was evaluated using TaqMan probes
from Applied Biosystems (Foster City, CA, USA), following the manufac-
turer’s guidelines (Supplementary Table 9).
Gene expression normalization and molecular subtype deﬁnition
Publicly available gene expression data from 311 TNBC patients were collected
(Supplementary Table 1) and used for correlative analysis. An additional cohort
of 137 TNBC patients treated with adjuvant chemotherapy was analyzed to
validate our ﬁndings from the discovery phase (Supplementary Table 1).
Detailed in silico analyses are reported in Supplementary Methods.
Cell cultures, treatments, and preparation of tumor-conditioned
media
Breast cancer cell lines (BT-474, BT-483, BT-549, HCC38, HCC70, HCC1143,
Hs578T, MCF-7, MDA-MB-157, MDA-MB-453, MDA-MB-231, MDA-MB-361,
MDA-MB-436, MDA-MB-468, and T47D) were obtained from the American
Type Culture Collection (Manassas, VA, USA), and grown according to the
standard protocols at 37 °C with 5% CO2. Paclitaxel, doxorubicin, and R428
(Selleck Chemicals, Houston, TX, USA) were dissolved in dimethyl sulfoxide.
Cells were treated with paclitaxel (25 nmol/l), doxorubicin (1 μmol/l), R428
(1 μmol/l), or control vehicle. Once grown to sub-conﬂuence, cells were
serum starved and incubated with fresh medium for 24 h. CM were
collected and ﬁltered at 0.2 μm.
Macrophages differentiation
Human monocytes were obtained from normal donor buffy coat by two-step
gradient centrifugation and then polarized. Detailed procedures are described
in Supplementary Methods. Freshly isolated human monocytes were also
cultured in the absence or presence of 30% CM from HCC38, MCF-7, MDA-
MB-231, MDA-MB-436, or MDA-MB-468 for 6 days, as previously described.12,44
Flow cytometry
Macrophages were treated as indicated in the text, and analyzed by ﬂow
cytometry on a FACS Canto ﬂow cytometer (BD Biosciences, San Jose, CA,
USA). Human FcRs were blocked using 1% human serum in phosphate-
buffered saline. Cells were washed, resuspended in FACS buffer (0.5%
bovine serum albumin and 0.05% NaN3 in phosphate-buffered saline), and
stained with ﬂuorochrome-conjugated monoclonal antibodies against
CD163 and CD206, or appropriate isotype controls (BD Biosciences).
Enzyme-linked immunosorbent assay
The levels of CCL18, IL-10, IL-12, and growth arrest-speciﬁc 6 (Gas6) in
macrophage supernatants were measured by commercially available ELISA
kits according to manufacturer’s instructions (R&D Systems). All experi-
ments were performed with three wells for each condition and repeated
four times.
Cell viability and wound-healing assays
Viable cells were identiﬁed using the 3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyltetrazolium bromide assay (Sigma Aldrich, Milan, Italy), as
previously described.45 For the wound-healing assay, breast cancer cells
were seeded in six-well plates, and then scraped with a pipette tip.
A detailed description of the assays can be found in Supplementary
Methods.
Western blotting
Immunodetection of proteins was performed using standard protocols.
Further details on immunoblotting are provided in Supplementary
Methods. The phospho-AXL (Tyr779) and AXL antibodies were purchased
from R&D Systems. The phospho-AKT (Ser473), AKT, phospho-ERK1/2
(Thr202/Tyr204), ERK1/2, phospho-SRC (Tyr416), SRC, and β-actin were
from Cell Signaling Technology (Danvers, MA, USA).
Statistical analysis
Differences between two groups were determined using the Student’s
t-test. Spearman’s rank and Pearson’s linear correlation tests were used to
evaluate the correlation between variables. Clinicopathological associa-
tions were tested using Fisher’s exact test. Co-expression and enrichment
analyses were performed using the Search-based Exploration of Expression
Compendium (SEEK; http://seek.princeton.edu).46 Pathway analysis was
performed using Ingenuity Pathway Analysis software (Qiagen, Redwood
City, CA, USA). Survival analyses were performed by the Kaplan–Meier
method, log-rank test (Mantel–Cox), and Cox univariate proportional
hazard model. Multivariate Cox proportional hazard regression analysis
was adjusted for relevant clinical covariates, including age at diagnosis,
histological grade, lymph node status, tumor size, and tumor stage. P
values were corrected using the Bonferroni or the Benjamini–Hochberg
methods as indicated in the text. All tests were two-sided and the level of
statistical signiﬁcance was set at Po0.05. Statistical analyses were
performed using GraphPad Prism version 5 (GraphPad Software, La Jolla,
CA, USA), Epi Info version 7 (CDC, Atlanta, GA, USA), and R software (http://
www.r-project.org). Further details on statistical methods are described in
Supplementary Methods.
Availability of data and materials
Information on the publicly available breast cancer data sets used in this
study is provided in Supplementary Table 1.
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